Literature DB >> 7926295

Monokine antagonism is reduced in patients with IDDM.

T Mandrup-Poulsen1, F Pociot, J Mølvig, L Shapiro, P Nilsson, T Emdal, M Røder, L L Kjems, C A Dinarello, J Nerup.   

Abstract

Interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-alpha) have been implicated as immune effector molecules in the pathogenesis of insulin-dependent diabetes mellitus (IDDM). Recently, an increased frequency of the A1/A1 genotype of an IL-1 receptor antagonist (IL-1Ra) gene polymorphism was observed in patients with IDDM. Therefore, we investigated plasma IL-1Ra and soluble TNF p55 receptor (TNFsRp55) levels in 18 men with recent-onset IDDM, 10 men with long-standing IDDM, and 35 age-matched healthy men. No differences in plasma IL-1Ra were found among the three groups. However, when the plasma IL-1Ra levels in the subjects with IDDM and the control subjects were analyzed according to IL-1Ra genotypes, we found a 30% lower level of plasma IL-1Ra in subjects with IDDM carrying the A1/A1 genotype compared with the levels in those carrying the A1/A2 genotype (372 +/- 40 vs. 530 +/- 54 ng/l, respectively, P = 0.025). In contrast, no significant association was seen between plasma IL-1Ra and IL-1Ra genotype in the control subjects. The TNFsRp55 level in heparinized plasma was 17% lower in patients with IDDM than in control subjects (3.93 +/- 0.22 vs. 4.72 +/- 0.24 micrograms/l, respectively, P = 0.038). These findings could not be explained by metabolic derangement in the IDDM patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7926295     DOI: 10.2337/diab.43.10.1242

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  14 in total

Review 1.  Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease.

Authors:  S T Azar; H Tamim; H N Beyhum; M Z Habbal; W Y Almawi
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1beta after live yellow fever vaccination.

Authors:  U T Hacker; S Erhardt; K Tschöp; T Jelinek; S Endres
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

Review 3.  Blockade of interleukin 1 in type 1 diabetes mellitus.

Authors:  Thomas Mandrup-Poulsen; Linda Pickersgill; Marc Yves Donath
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

4.  Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment.

Authors:  F E Clay; J K Tarlow; M J Cork; A Cox; M J Nicklin; G W Duff
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

Review 5.  The role of interleukin-1 in the pathogenesis of IDDM.

Authors:  T Mandrup-Poulsen
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

6.  Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus.

Authors:  A I Blakemore; A Cox; A M Gonzalez; J K Maskil; M E Hughes; R M Wilson; J D Ward; G W Duff
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

7.  Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty.

Authors:  S E Francis; N J Camp; A J Burton; R M Dewberry; J Gunn; A Stephens-Lloyd; D C Cumberland; A Gershlick; D C Crossman
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

8.  Identification of a novel type 1 diabetes susceptibility gene, T-bet.

Authors:  Yuka Sasaki; Kenji Ihara; Nobuo Matsuura; Hitoshi Kohno; Seiho Nagafuchi; Ryuichi Kuromaru; Koichi Kusuhara; Ryu Takeya; Timothy Hoey; Hideki Sumimoto; Toshiro Hara
Journal:  Hum Genet       Date:  2004-07-06       Impact factor: 4.132

9.  Large-Scale Discovery and Validation Studies Demonstrate Significant Reductions in Circulating Levels of IL8, IL-1Ra, MCP-1, and MIP-1β in Patients With Type 1 Diabetes.

Authors:  Sharad Purohit; Ashok Sharma; Diane Hopkins; Leigh Steed; Bruce Bode; Stephen W Anderson; John Chip Reed; R Dennis Steed; Tao Yang; Jin-Xiong She
Journal:  J Clin Endocrinol Metab       Date:  2015-07-09       Impact factor: 5.958

10.  Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

Authors:  Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Jan A Ehses; Marc Y Donath; Thomas Mandrup-Poulsen
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.